Summit Therapeutics Inc. Stock-Based Compensation
Summit Therapeutics Inc. (SMMT) reported Stock-Based Compensation of $141.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-07-23
- Summit Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $68.71M, a 85.65% decline year-over-year.
- Summit Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $72.79M, a 556.01% increase year-over-year.
- Summit Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $111.78M, a 914.79% increase year-over-year.
- Summit Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $130.76M, a 575.03% increase year-over-year.
- Summit Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $732.42M, a 1336.65% increase from fiscal 2024.
- Summit Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $50.98M, a 261.36% increase from fiscal 2023.
- Summit Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $14.11M, a 18.08% increase from fiscal 2022.
- Summit Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $11.95M, a 6.69% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 11 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $68.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $141.50M 10-Q · filed 2026-07-23 | $253.28M derived: sum of 3 quarters · filed 2026-07-23 | $384.04M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2026-03-31 | $72.79M 10-Q · filed 2026-04-30 | $184.57M derived: sum of 2 quarters · filed 2026-04-30 | $315.33M derived: sum of 3 quarters · filed 2026-04-30 | $794.12M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-12-31 | $111.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $242.54M derived: sum of 2 quarters · filed 2026-02-23 | $721.32M derived: sum of 3 quarters · filed 2026-07-23 | $732.42M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $130.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $609.54M derived: sum of 2 quarters · filed 2026-07-23 | $620.64M 10-Q · filed 2025-10-20 | $631.66M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-06-30 | $478.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $489.88M 10-Q · filed 2026-07-23 | $500.89M derived: sum of 3 quarters · filed 2026-07-23 | $520.27M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-03-31 | $11.10M 10-Q · filed 2026-04-30 | $22.11M derived: sum of 2 quarters · filed 2026-04-30 | $41.48M derived: sum of 3 quarters · filed 2026-04-30 | $52.57M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $11.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $30.39M derived: sum of 2 quarters · filed 2026-02-23 | $41.47M derived: sum of 3 quarters · filed 2026-02-23 | $50.98M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $19.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $30.46M derived: sum of 2 quarters · filed 2025-10-20 | $39.97M 10-Q · filed 2025-10-20 | $48.72M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | $11.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $20.59M 10-Q · filed 2025-08-11 | $29.35M derived: sum of 3 quarters · filed 2026-02-23 | $30.05M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $9.51M 10-Q · filed 2025-05-01 | $18.26M derived: sum of 2 quarters · filed 2026-02-23 | $18.96M derived: sum of 3 quarters · filed 2026-02-23 | $20.84M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | $8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $9.46M derived: sum of 2 quarters · filed 2026-02-23 | $11.33M derived: sum of 3 quarters · filed 2026-02-23 | $14.11M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $705.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $2.58M derived: sum of 2 quarters · filed 2024-10-30 | $5.36M 10-Q · filed 2024-10-30 | $8.01M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.65M 10-Q · filed 2024-08-06 | $7.31M derived: sum of 3 quarters · filed 2025-02-24 | $10.11M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-03-31 | $2.77M 10-Q · filed 2024-05-01 | $5.43M derived: sum of 2 quarters · filed 2025-02-24 | $8.23M derived: sum of 3 quarters · filed 2025-02-24 | $10.73M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2022-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $5.46M derived: sum of 2 quarters · filed 2025-02-24 | $7.95M derived: sum of 3 quarters · filed 2025-02-24 | $11.95M 10-K · filed 2025-02-24 | |
| 2022-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $5.29M derived: sum of 2 quarters · filed 2023-11-07 | $9.29M 10-Q · filed 2023-11-07 | $14.91M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $6.49M 10-Q · filed 2023-08-09 | $12.11M derived: sum of 3 quarters · filed 2023-08-09 | $14.76M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $4.00M 10-Q · filed 2023-05-11 | $9.62M derived: sum of 2 quarters · filed 2023-05-11 | $12.26M derived: sum of 3 quarters · filed 2023-05-11 | $15.93M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $8.26M derived: sum of 2 quarters · filed 2023-03-09 | $11.94M derived: sum of 3 quarters · filed 2023-03-09 | $12.80M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $6.32M derived: sum of 2 quarters · filed 2022-11-09 | $7.18M 10-Q · filed 2022-11-09 | $7.76M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-06-30 | $3.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $4.54M 10-Q · filed 2022-08-11 | $5.12M derived: sum of 3 quarters · filed 2022-12-21 | $5.48M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-03-31 | $868.00K 10-Q · filed 2022-05-11 | $1.45M derived: sum of 2 quarters · filed 2022-12-21 | $1.81M derived: sum of 3 quarters · filed 2022-12-21 | $2.34M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2020-12-31 | $578.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $939.00K derived: sum of 2 quarters · filed 2022-12-21 | $1.47M derived: sum of 3 quarters · filed 2022-12-21 | $1.77M 10-K/A · filed 2022-12-21 | |
| 2020-09-30 | $361.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $891.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.19M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $530.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $827.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $297.00K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | $845.00K 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $244.00K derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | $848.00K 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | $604.00K 8-K · filed 2020-09-29 | ||||
| 2019-01-31 | $6.29M 10-K · filed 2021-03-31 | ||||
| 2018-01-31 | $2.09M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |